Multicenter Trial of Prednisone in Alzheimer's Disease

National Institutes of Health (NIH)

Status and phase: Completed; Phase 3

Conditions: Alzheimer Disease

Treatments: Drug: Prednisone

Study type: Interventional

Funder types: NIH

Identifiers

NCT00000178

3U01AG010483-08S2 (U.S. NIH Grant/Contract)

IA0002

Details and patient eligibility

About

This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Alzheimer's disease who are in stable medical condition

Exclusion criteria

• Patients with diabetes or severe osteoporosis